Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. director Charles Lazelle Sawyers filed an initial Form 3 reporting his ownership in the company. He directly holds 1,946 American Depositary Shares and 4 ordinary shares as of June 11, 2026. Each American Depositary Share represents 13 ordinary shares.
BeOne Medicines Ltd. director Elizabeth Fisher Mooney has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing summary in this excerpt shows no reported purchases, sales, exercises, gifts, restructurings, or other equity transactions and no listed holdings.
Baker Bros. Advisors and related entities report beneficial ownership of approximately 115.9 million Ordinary Shares, representing 8.0% of the Ordinary Shares of the issuer, primarily through American Depositary Shares. The ownership is held across Baker Bros. funds and affiliated entities, with the adviser exercising voting and investment power.
On June 11, 2026, Felix J. Baker, Ph.D. was elected to the issuer’s board of directors as Lead Director, while prior directors and adviser employees Michael Goller and Ranjeev Krishana did not stand for re‑election and left the board. In connection with his election, Felix Baker received 18,980 restricted share units that vest into Ordinary Shares, subject to continued board service. The filing also details option and RSU holdings and clarifies that compensation received by adviser employees serving as directors is for the economic benefit of the Baker funds.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported a compensation-related equity grant linked to its board. On June 11, 2026, the company granted 18,980 restricted share units payable solely in ordinary shares to Felix J. Baker in connection with his election to the board under the 2016 Share Option and Incentive Plan. The RSUs vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service. Due to the Baker Bros. fund structure, the RSU grant and resulting ordinary shares are reflected as indirect proportionate pecuniary interests of affiliated funds, with investment adviser Baker Bros. Advisors LP holding voting and dispositive power. The filing also notes indirect and direct holdings of American Depositary Shares, with each ADS representing 13 ordinary shares.
ONC affiliate filed a Section 144 notice to sell 945 ADS. The filing states the ADS arise from restricted stock vesting under a registered plan and lists a planned cash sale with an anticipated sale date of 05/26/2026.
The filing also reports that 212 ADS were sold on 05/22/2026 for $65,632.97. The form bears a filing reference date of 06/15/2026.
ONC filing a Form 144 notifies the proposed sale of 1,484 ADS on 06/08/2026 for $399,738.11. The filing also lists 626 ADS tied to restricted stock vesting under a registered plan with a 06/10/2026 date.
Issuer filed a notice under Rule 144 to sell ADSs. The filing lists 756 ADS to be sold in connection with restricted stock vesting under a registered plan with an effective date of 06/10/2026. The excerpt also reports 1,367 ADS sold on 06/08/2026.
The issuer filed a Form 144 notice related to 631 ADS tied to restricted stock vesting under a registered plan with a vesting date of 06/10/2026 and a filing date of 06/11/2026. The notice lists Morgan Stanley Smith Barney LLC as the broker-dealer.
ONC submitted a Rule 144 notice regarding proposed sales of American Depositary Shares (ADS). The filing lists an ADS quantity 43,466.56, an identifier 54,885,669, and dates including 06/10/2026 and 06/11/2026. The filer named is Titus Benjamin Ball.
ONC: proposed disposition of American Depositary Shares reported on Form 144. The filing names Chan Lee and shows a proposed sale of 428 ADS on 06/10/2026 related to Restricted Stock Vesting Under a Registered Plan. The notice also lists recent sales: 871 ADS on 06/08/2026 for $235,539.13, 332 ADS on 05/13/2026 for $103,159.04, 332 ADS on 04/08/2026 for $103,447.88, and 341 ADS on 03/11/2026 for $102,300.00.